about
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesChallenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities.A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.Cost-Effectiveness of Dengue Vaccination Programs in BrazilCervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.Modeling optimal cervical cancer prevention strategies in Nigeria.Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women.Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate.An updated natural history model of cervical cancer: derivation of model parameters.How protective is cervical cancer screening against cervical cancer mortality in developing countries? The Colombian case.Forecasting the economic value of an Enterovirus 71 (EV71) vaccineEstimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.A school-based human papillomavirus vaccination program in barretos, Brazil: final results of a demonstrative study.Health and economic implications of HPV vaccination in the United States.Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.Emerging vaccine informatics.Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil.Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa.Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil.Resources Required for Cervical Cancer Prevention in Low- and Middle-Income CountriesHPV and cervical cancer: screening or vaccination?The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting.New technologies for cervical cancer screeningHealth and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.Economic evaluation of human papillomavirus vaccination in the United Kingdom.Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model.Structural differences among cost-effectiveness models of human papillomavirus vaccines.Modeling cervical cancer prevention in developed countries.Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact.The cost effectiveness of human papillomavirus vaccines: a systematic review.Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Cervical cancer control in Latin America: A call to action.Cost Effectiveness of HPV Vaccination: A Systematic Review of Modelling Approaches.
P2860
Q24655328-98C650B8-A2F6-49CC-B17E-D84E10ECA14FQ30245295-48368083-52A5-4A1F-936A-32F7225A4B5FQ33344903-809A03B4-A3F0-4C64-8E41-ADE1AA41EF64Q33514126-C9176054-9395-4118-96B1-0FA54C63DB65Q33636857-153790A6-738E-4DA7-9D92-EB006615C7DAQ33692293-1F36AFCA-EFEC-4464-B668-57AF2242B93BQ33755002-48D41E61-4212-4160-9FAC-9256A9152781Q33761437-7C1B1530-65D6-48FB-BB24-2D5685746659Q33898840-02A460E1-9134-4AD4-9541-E5C675C53A1EQ33934529-77F8AB38-CC17-4E07-B5FA-B43DC5AED984Q34072409-C22F10E7-FD3B-40AA-97DD-DA1FE7CB52DEQ34083083-063E2FAD-C5B8-48D6-BB97-2F1D3092861FQ34174619-823003E0-FD2D-442A-8EE0-C77373E68DD3Q34338981-0C1B7071-30C9-4689-BFFE-77F38E4312E1Q34437088-6AFED55A-D6F1-46A4-B88E-026CAB5744FBQ34701904-E9F5683E-CBC0-43E6-B00E-25FCD2539685Q34824304-7797FE78-5512-4074-A5B0-DECBD2255B13Q34997604-29750178-C0C3-4454-830D-C9642E2302D0Q35100809-3BF4B75B-116E-45E5-9855-5216A5D913C6Q35117498-C33B4F6E-AE0E-4B7F-885E-5A35366C55CCQ35565207-1E4F1176-042A-46A9-B1B9-1CDF48C62BA8Q35858737-AEA88B59-4674-43F2-9922-D1BF4BBED593Q35886544-E9500743-7AF3-4995-AF58-89CDC0258045Q36154922-85FC503D-6EA4-480B-8254-4C1C33CFC4AEQ36608826-78244F93-DC5E-4135-ABEC-F440BAE14663Q36611500-1C34DFB6-81C7-466C-81E0-F838C201C66FQ36784424-BA295AAD-0B01-44BA-9551-1DC118202FC0Q36785915-19B1A9DA-36AB-4926-82BF-069AE0F61341Q36818045-DAB742C7-433C-4F6B-9824-67E6879D7E69Q37011809-0220CFFE-A3FB-48D5-984B-8DD8B93282C1Q37076741-F76465A2-B164-4CF3-BEC3-94D995DA219FQ37259581-91B55061-876D-44D3-9614-0F15FAE62617Q37291448-18326D5B-9424-4C2B-AF03-8E88BCFA981EQ37321084-A05A72E9-FB04-4804-A72D-91216A88662BQ37912228-574C84A3-6355-477A-B0F6-0AE9A503F180Q37993109-42CDAB1E-C34E-4B96-8E2F-6740759CCDC6Q38027575-7B1D3CA3-809C-4869-86EE-8642094B2E8AQ38549643-E64189B8-1251-47B7-8D38-23BEEE900E9CQ38670183-E4535E3F-3C10-4973-9D3F-A66D9252445BQ38834076-2C01B525-F5C2-4444-998F-7531E946594B
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@en
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@nl
type
label
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@en
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@nl
prefLabel
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@en
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@nl
P2093
P50
P1433
P1476
Cost-effectiveness of HPV 16, 18 vaccination in Brazil.
@en
P2093
F Xavier Bosch
Jane J Kim
Katie Kobus
Meredith K H O'shea
P304
P356
10.1016/J.VACCINE.2007.05.058
P407
P577
2007-06-15T00:00:00Z